There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Universal Health (UHS – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $110.00. The company’s shares closed last Wednesday at $91.20.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $111.81 average price target, implying a 20.6% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $140.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Universal Health (UHS)
In a report released yesterday, Steve Baxter from Wells Fargo maintained a Buy rating on Universal Health, with a price target of $200.00. The company’s shares closed last Wednesday at $165.90.
According to TipRanks.com, Baxter is a 3-star analyst with an average return of
Universal Health has an analyst consensus of Moderate Buy, with a price target consensus of $187.64, a 14.3% upside from current levels. In a report issued on April 12, Deutsche Bank also maintained a Buy rating on the stock with a $203.00 price target.
Biogen (BIIB)
Scotiabank analyst George Farmer maintained a Buy rating on Biogen today and set a price target of $275.00. The company’s shares closed last Wednesday at $201.99, close to its 52-week low of $189.44.
According to TipRanks.com, Farmer is a 4-star analyst with an average return of
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $285.09, representing a 43.3% upside. In a report issued on April 22, Piper Sandler also maintained a Buy rating on the stock with a $325.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- BioMarin Reports Record Financial Results for the First Quarter 2024
- BioMarin price target raised to $110 from $100 at Cantor Fitzgerald
- Biomarin Pharmaceutical Inc. (BMRN) Q1 Earnings Cheat Sheet
- BioMarin participates in a conference call with JPMorgan.
- BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia
